Teva Pharmaceuticals and IBM Partner to Build Global e-Health Solutions on the IBM Watson Health Cloud

IBMIBM (NYSE: IBM) Watson Health and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that Teva has been selected as its first Foundational Life Sciences Partner for the Watson Health Cloud. As part of this new strategic partnership, Teva becomes the first global pharmaceutical company to tap the power of the Watson Health Cloud to benefit patients and healthcare providers across geographies.

Teva has chosen the IBM Watson Health Cloud as a preferred global technology platform and aims to build solutions designed to help millions of individuals worldwide with complex and chronic conditions such as asthma, pain, migraine and neurodegenerative diseases. In addition, a joint Teva-IBM Research team will deploy Big Data and machine learning technology to create disease models and advanced therapeutic solutions.

"Teva is actively exploring the e-health evolution with a strong focus on fulfilling unmet and emerging patients' needs. The IBM Watson Health Cloud provides a strong foundation on which we can realize this vision," said Guy Hadari, SVP and CIO for Teva Pharmaceutical Industries Ltd. "By building on the Watson Health Cloud, we believe Teva will be in a unique position to put the best information and insights in the hands of physicians, care teams and patients, to empower treatment optimization for individuals and populations across the spectrum of acute and chronic conditions. Watson holds promise to provide Teva with better insights, real-time feedback and options for clinicians to consider to improve patient care."

Watson is a groundbreaking cognitive computing platform that represents a new era of computing based on its ability to interact in natural language, process vast amounts of Big Data to uncover patterns and insights, and learn from each interaction. The Watson Health Cloud provides an open development platform for physicians, researchers, insurers and companies focused on creating health and wellness solutions.

Teva will work with IBM on long-range platform and solutions development, with experts collaborating to enhance IBM Watson Health Cloud capabilities and explore synergies with existing Watson Health ecosystem partners. The company, which has one of the world's largest portfolios of medicines, expects to develop solutions designed to collect and analyze real world evidence, draw powerful insights and inform a variety of initiatives such as reducing drug misuse or increasing prescribed medication adherence.

"Teva's pioneering digital health vision, reach across global markets, extensive portfolio of medicines and significant industry experience make them a preferred life science ecosystem partner for the Watson Health Cloud," said Mike Rhodin, senior vice president, IBM Watson.

IBM's Global Business Services will work closely with a Teva Analytics team to assess the data and the analytics model requirements for the Real World Evidence e-health solution.

IBM Watson: Pioneering a New Era of Computing
Watson is the first commercially available cognitive computing capability representing a new era in computing. The system, delivered through the cloud, analyzes high volumes of data and complex questions posed in natural language and proposes evidence-based answers. Watson is continuously gaining in value and knowledge over time, from previous interactions.

In January 2014, IBM launched the IBM Watson unit, a business dedicated to developing and commercializing cloud-delivered cognitive computing technologies. The move signified a strategic shift by IBM to deliver a new class of software, services and apps that improves by learning, and discovers insights from massive amounts of Big Data. As part of the unit, the company has increased the number and diversity of cognitive computing services delivered to its partners, adding new beta Watson services in February 2015, and scalable deep learning APIs with the acquisition of AlchemyAPI in March 2015.

In April 2015, the company continued to build on its strengths in cognitive computing, analytics, security and cloud with the launch of IBM Watson Health and the Watson Health Cloud platform. The new unit will help improve the ability of doctors, researchers and insurers to innovate by surfacing new insights from the massive amount of personal health data being created daily. The Watson Health Cloud allows this information to be anonymized, shared and combined with a dynamic and constantly growing aggregated view of clinical, research and social health data that clients choose to share.

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2014 amounted to $20.3 billion.

Most Popular Now

Hull University Teaching Hospitals NHS T…

Hull University Teaching Hospitals NHS Trust has deployed DXC Technology's (NYSE:DXC) cloud-based Clinical Aide mobile application, which both improves secure access to electronic patient medical records and increases patient and...

Central Hospital in Finland Automates Sy…

This November Central Ostrobothnia Central Hospital in Finland has started symptom tracking and remote monitoring of corona virus-infected patients with the Buddy Healthcare mobile application and clinical monitoring platform. The...

Ultrapotent COVID-19 Vaccine Candidate D…

An innovative nanoparticle vaccine candidate for the pandemic coronavirus produces virus-neutralizing antibodies in mice at levels ten-times greater than is seen in people who have recovered from COVID-19 infections. Designed...

Interactive virtual reality emerges as a…

Bristol scientists have demonstrated a new virtual reality [VR] technique which should help in developing drugs against the SARS-CoV-2 virus - and enable researchers to share models and collaborate in...

Softphone App to Save NHS up to £20 Mill…

GPs and patients are to benefit from a new softphone app that will eliminate almost all the "hidden cost" of calls for remote consultations and is forecast to save the...

More than 1,000 Exhibitors have Already …

16 - 19 November 2020, Düsseldorf, Germany. This year, the world's largest and leading medical trade fair, MEDICA, and the number one international event for the medical technology manufacturing supplier market...

DMEA Newcomer Award: The Search is on fo…

13 - 15 April 2021, Berlin, Germany. More efficient, digital and patient-friendly! Tomorrow's healthcare system promises great things. And to ensure this becomes reality a fresh impetus and creative ideas are...

App to Help NHS Prevent Deadly Hospital …

Compass app to help NHS trusts prevent hospital-acquired acute kidney injury and pneumonia - both of which cause harm to COVID-19 patients and can be fatal. Hospitals could alleviate pressure...

Leeds Deploys Imaging Tech for Advanced …

A multi-million pound initiative that is digitising, connecting and applying artificial intelligence to NHS pathology services in the North of England has taken an important step, after Leeds Teaching Hospitals...

Survey of COVID-19 Research Provides Fre…

Researchers at Karolinska Institutet in Sweden have explored all COVID-19 research published during the initial phase of the pandemic. The results, which were achieved by using a machine learning-based approach...

South Tees Signs Major Deal with Alcidio…

South Tees Hospitals NHS Foundation Trust has signed a major deal with smart health technology provider Alcidion. An entire range of new technology capabilities will alleviate pressure for busy NHS...